西格列汀或瑞格列奈联合甘精胰岛素治疗2型糖尿病的临床研究  

Sitagliptin as add-on to glargine insulin versus repaglinide as add-on to glargine insulin in the treatment of T2DM—A report of clinical observation

作　　者：余筱燕[1] 赵廷启[1] 

机构地区：[1]宁波大学医学院附属医院内分泌科,315020

出　　处：《中国糖尿病杂志》2013年第4期336-338,共3页Chinese Journal of Diabetes

摘　　要：目的比较西格列汀联合甘精胰岛素与瑞格列奈联合甘精胰岛素治疗T2DM的疗效。方法将140例口服降糖药(OAD)血糖控制不佳的T2DM患者随机分为西格列汀联合甘精胰岛素组(观察组)和瑞格列奈联合甘精胰岛素组(对照组),治疗12周,观察HbA1c、FPG、2hPG、BMI等指标及胰岛素用量、低血糖发生情况。结果治疗后两组HbA1c、FPG、2hPG较治疗前均有下降(P<0.05);观察组与对照组HbA1c达标率分别为85.7%、87.2%(P>0.05),但观察组胰岛素用量比对照组减少了11.4%,且BMI得到控制,低血糖发生率低。结论西格列汀联合甘精胰岛素治疗可有效控制血糖和体重,减少低血糖事件,在同等HbA1c达标率下,所用的胰岛素剂量更少。Objective To compare the efficacy of sitagliptin plus glargine insulin versus repaglinide plus glargine insulin in treatment of T2DM patients. Methods The 140 T2DM patients who were inadequately controlled by oral anti-diabetic agent were randomized into sitagliptin plus glargine insulin （observation group） or repaglinide plus glargine insulin （control group）. The duration of treatment was 12 weeks. HbA1 c, FPG, 2 hPG, BMI and dosage of insulin as well as hypoglycemia events were recorded to assess the result of treatment. Results After treatment, HbA1c, FPG, and 2 hPG were significantly decreased compared to pretreatment（P〈0. 05）; HbAlc targeting rate was 85.7% in observation group versus 87. 2% in control group, with no significant difference, while the dosage of insulin in observation group was decreased by 11.4%compared to control group, with decreased BMI and low incidence of hypoglycemia. Conclusion Sitagliptin plus glargine insulin can effectively control blood glucose and body weight with low incidence of hypoglycemia and much less insulin dosage under the same HbA1 c targeting rate. Sitagliptin plus glargine insulin is a good combination therapy to treat T2DM.

关 键 词：西格列汀 甘精胰岛素 瑞格列奈 糖尿病 2型 

分 类 号：R587.1[医药卫生—内分泌]